FRM
IMVT icon

Fox Run Management’s Immunovant IMVT Stock Holding History

Fox Run Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,428
Closed -$229K – 1030
2025
Q1 		$229K Buy
+13,428
New +$281K 0.04% 759
2024
Q1 		– Sell
-14,534
Closed -$612K – 916
2023
Q4 		$612K Buy
+14,534
New +$535K 0.16% 226
2023
Q2 		– Sell
-12,882
Closed -$200K – 815
2023
Q1 		$200K Buy
12,882
+102
+0.8% +$1.77K 0.07% 532
2022
Q4 		$227K Buy
+12,780
New +$161K 0.09% 450
2022
Q1 		– Sell
-10,803
Closed -$92K – 603
2021
Q4 		$92K Sell
10,803
-3,109
-22% -$25.7K 0.05% 423
2021
Q3 		$121K Buy
+13,912
New +$125K 0.08% 414

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Fox Run Management's IMVT Position: Q2 2025 in Review

Fox Run Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 13,428 shares — an estimated $229K sold.

Fox Run Management first reported a position in IMVT in Q3 2021 and held it in 6 quarters. The position peaked at $612K in Q4 2023. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Fox Run Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 13,428 Immunovant shares in Q2 2025, an estimated $229K.
  • Fox Run Management first reported a position in Immunovant in Q3 2021 and held it in 6 quarters.
  • Fox Run Management's Immunovant position peaked at $612K in Q4 2023.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.